Health · Ai
PAQ Therapeutics
PAQ Therapeutics is a clinical-stage biotechnology company in Burlington, Massachusetts developing a new class of small-molecule degraders that harness autophagy, the body's natural cellular recycling system, to destroy disease-causing proteins. Its proprietary ATTEC (autophagosome-tethering compound) platform aims to eliminate targets that traditional inhibitors cannot reach. The company's lead programs are KRAS degraders - PT0253, a selective KRAS G12D degrader, and PT0511, a pan-KRAS degrader - both in Phase 1 clinical trials for lung, colorectal and pancreatic cancers driven by KRAS mutations.